Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 0.73 |
| ▸ | PPARA | Q07869 | 9/20 | 0.73 |
| ▸ | PPARG | P37231 | 5/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655979 | 0.90 | PPARD (0.89) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL23870962 | 0.88 | PPARD (0.56) | PPARDPPARAPPARG | |
| SCHEMBL6613317 | 0.88 | PPARD (0.70) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL4787001 | 0.87 | PPARD (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL1765944 | 0.87 | PPARD (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL1673096 | 0.87 | PPARD (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6615277 | 0.87 | PPARD (0.70) | PPARDPPARAPPARG | |
| SCHEMBL12732524 | 0.87 | PPARD (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL4751894 | 0.87 | PPARD (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL8220658 | 0.85 | PPARD (0.65) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092517-A1 | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092517-A1 | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.